Related Experiment Video
Updated: Jun 29, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Matheus Henrique Dias1, Anoek Friskes2, Siying Wang3
1Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Inhibiting protein phosphatase 2A (PP2A) and WEE1 together hyperactivates oncogenic pathways, causing cancer cell death. Acquired resistance paradoxically leads to tumor suppression, suggesting a novel therapeutic strategy for colon cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer homeostasis relies on balancing oncogenic signaling and stress responses.
- While oncogenic pathway inhibition is common, pathway overactivation can also be lethal.
- Protein phosphatase 2A (PP2A) inhibition can paradoxically activate oncogenic pathways and stress responses.
Purpose of the Study:
- To investigate the effects of PP2A inhibition on colon cancer cells.
- To identify synergistic drug combinations for cancer therapy.
- To explore the mechanisms of acquired resistance to novel cancer treatments.
Main Methods:
- Genetic and compound screens were employed.
- Inhibition of PP2A and WEE1 was tested in multiple cancer models.
- Patient-derived tumors were used for in vivo studies.
- Mechanisms of acquired resistance were analyzed.
Main Results:
- PP2A inhibition hyperactivated oncogenic pathways and stress responses in colon cancer.
- Combined inhibition of PP2A and WEE1 synergistically collapsed DNA replication and induced cell death.
- This combination suppressed patient-derived tumor growth in vivo.
- Acquired resistance to the combination therapy resulted in suppressed tumor formation in vivo.
Conclusions:
- Paradoxical activation of oncogenic signaling can lead to tumor suppression.
- Combined PP2A and WEE1 inhibition represents a potent anti-cancer strategy.
- Tumor-suppressive drug resistance may arise from loss of oncogenic signaling.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation

